Musashi1 as a potential therapeutic target and diagnostic marker for lung cancer
Metrics: PDF 1950 views | HTML 1955 views | ?
Xiao-Yang Wang1,*, Huina Yu2,*, R. Ilona Linnoila1, Laodong Li2, Dangyu Li3, Biwen Mo2, Hideyuki Okano4, Luiz O. F. Penalva5, and Robert I. Glazer6
1 Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
2 Division of Respiratory Diseases, Guilin Medical University Hospital, Guilin, Guangxi, P.R. China
3 Division of Respiratory Diseases, Nan Xi Shan Hospital, Guilin Medical University Hospital, Guilin, Guangxi, P.R. China
4 Department of Physiology, Keio University, Tokyo, Japan
5 Children’s Cancer Research Institute, Department of Cell and Structural Biology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA
6 Department of Oncology, Georgetown University, and Lombardi Comprehensive Cancer Center, Washington, DC, USA
* Contributed equally to this work
Robert I. Glazer, email:
Biwen Mo, email:
Keywords: Musashi1, lung cancer, shRNA, β-catenin, notch, numb
Received: May 15, 2013, Accepted: May 19, 2013, Published: May 21, 2013
Lung cancer remains one of the leading causes of cancer-related deaths worldwide with a 5-year survival rate of less than 20%. One approach to improving survival is the identification of biomarkers to detect early stage disease. In this study, we investigated the potential of the stem cell and progenitor cell marker, Musashi1 (Msi1), as a diagnostic marker and potential therapeutic target for lung cancer. Functional studies in A549 bronchioalveolar carcinoma and NCI-H520 squamous cell carcinoma cells revealed that Msi1 was enriched in spheroid cultures of tumor cells and in the CD133+ cell population. Downregulation of Msi1 by lentivirus-mediated expression of an Msi1 shRNA reduced spheroid colony proliferation. Growth inhibition was associated with reduced nuclear localization of β-catenin and inhibition of the processing of intracellular Notch. In primary lung cancer, Msi1 protein expression was elevated in 86% of 202 tissue microarray specimens, and Msi1 mRNA was increased in 80% of 118 bronchoscopic biopsies, including metastatic disease, but was rarely detected in adjacent normal lung tissue and in non-malignant diseased tissue. Msi1 was expressed in a diffuse pattern in most tumor subtypes, except in squamous cell carcinomas, where it appeared in a focal pattern in 50% of specimens. Thus, Msi1 is a sensitive and specific diagnostic marker for all lung cancer subtypes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.